AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
14 11 2023
Historique:
accepted: 30 07 2023
received: 05 06 2023
medline: 30 10 2023
pubmed: 15 8 2023
entrez: 15 8 2023
Statut: ppublish

Résumé

Acute myeloid leukemia with complex karyotype (CK-AML) is associated with poor prognosis, which is only in part explained by underlying TP53 mutations. Especially in the presence of complex chromosomal rearrangements, such as chromothripsis, the outcome of CK-AML is dismal. However, this degree of complexity of genomic rearrangements contributes to the leukemogenic phenotype and treatment resistance of CK-AML remains largely unknown. Applying an integrative workflow for the detection of structural variants (SVs) based on Oxford Nanopore (ONT) genomic DNA long-read sequencing (gDNA-LRS) and high-throughput chromosome confirmation capture (Hi-C) in a well-defined cohort of CK-AML identified regions with an extreme density of SVs. These rearrangements consisted to a large degree of focal amplifications enriched in the proximity of mammalian-wide interspersed repeat elements, which often result in oncogenic fusion transcripts, such as USP7::MVD, or the deregulation of oncogenic driver genes as confirmed by RNA-seq and ONT direct complementary DNA sequencing. We termed this novel phenomenon chromocataclysm. Thus, our integrative SV detection workflow combing gDNA-LRS and Hi-C enables to unravel complex genomic rearrangements at a very high resolution in regions hard to analyze by conventional sequencing technology, thereby providing an important tool to identify novel important drivers underlying cancer with complex karyotypic changes.

Identifiants

pubmed: 37582288
pii: 497453
doi: 10.1182/bloodadvances.2023010887
pmc: PMC10632680
doi:

Substances chimiques

USP7 protein, human EC 3.4.19.12
Ubiquitin-Specific Peptidase 7 EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6520-6531

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Nat Genet. 2018 Oct;50(10):1388-1398
pubmed: 30202056
Semin Oncol. 2008 Aug;35(4):365-77
pubmed: 18692687
Genome Res. 2018 Aug;28(8):1126-1135
pubmed: 29954844
Cell. 2011 Jan 7;144(1):27-40
pubmed: 21215367
Cell. 2013 Apr 25;153(3):666-77
pubmed: 23622249
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Genome Med. 2015 May 11;7(1):43
pubmed: 26019724
Leukemia. 2018 Jul;32(7):1609-1620
pubmed: 29472722
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897
DNA Res. 2017 Feb 1;24(1):59-69
pubmed: 28028040
Mob DNA. 2015 Jun 02;6:11
pubmed: 26045719
Blood. 2022 Sep 22;140(12):1345-1377
pubmed: 35797463
Genome Biol. 2020 Mar 23;21(1):73
pubmed: 32293513
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
BMC Genomics. 2014 Oct 08;15:879
pubmed: 25297679
Genome Biol. 2020 Mar 3;21(1):56
pubmed: 32127024
Blood Rev. 2019 Jul;36:70-87
pubmed: 31101526
Am J Hum Genet. 2020 Jun 4;106(6):872-884
pubmed: 32470376
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Trends Genet. 2016 Sep;32(9):530-542
pubmed: 27478068
J Virol. 2021 Sep 9;95(19):e0029921
pubmed: 34287049
Genome Biol. 2014;15(12):550
pubmed: 25516281
Signal Transduct Target Ther. 2018 Jun 29;3:17
pubmed: 29967688
Eur J Med Genet. 2014 Oct;57(10):567-70
pubmed: 25128687
Front Genet. 2021 Nov 18;12:761791
pubmed: 34868242
J Clin Oncol. 2017 Mar 20;35(9):934-946
pubmed: 28297624
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Nat Biotechnol. 2015 Mar;33(3):290-5
pubmed: 25690850
Genome Biol. 2017 Jun 27;18(1):125
pubmed: 28655341
Hum Reprod. 2018 Aug 1;33(8):1381-1387
pubmed: 30325427
Nat Commun. 2019 Jul 19;10(1):3240
pubmed: 31324872
Mob DNA. 2014 May 05;5:14
pubmed: 25018785
Genome Biol. 2019 Nov 20;20(1):246
pubmed: 31747936
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Commun. 2019 Apr 16;10(1):1784
pubmed: 30992455
Blood. 2012 Mar 1;119(9):2114-21
pubmed: 22186996
Genome Med. 2018 Dec 7;10(1):95
pubmed: 30526634
Cell Cycle. 2018;17(7):823-828
pubmed: 29616860
Nature. 2022 Nov;611(7935):387-398
pubmed: 36289338
Sci China Life Sci. 2020 May;63(5):675-687
pubmed: 32170627
Nat Rev Genet. 2011 May;12(5):363-76
pubmed: 21358748
Cell. 2013 Mar 14;152(6):1226-36
pubmed: 23498933

Auteurs

Marius-Konstantin Klever (MK)

Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.

Eric Sträng (E)

Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Sara Hetzel (S)

Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.

Julius Jungnitsch (J)

Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.
Human Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany.

Anna Dolnik (A)

Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Robert Schöpflin (R)

RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.
Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany.

Jens-Florian Schrezenmeier (JF)

Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Felix Schick (F)

Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Olga Blau (O)

Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Jörg Westermann (J)

Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Frank G Rücker (FG)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Zuyao Xia (Z)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Konstanze Döhner (K)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Hubert Schrezenmeier (H)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany.

Malte Spielmann (M)

Human Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Institut für Humangenetik Lübeck, Universität zu Lübeck, Lübeck, Germany.

Alexander Meissner (A)

Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.

Uirá Souto Melo (US)

RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.

Stefan Mundlos (S)

RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.
Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.

Lars Bullinger (L)

Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH